With over 20 years of experience, Lindsay has experience in all phases of practice before the U.S. Patent and Trademark Office including post-grant proceedings. His experience in opinion writing and litigation allows Lindsay to provide clients with effective strategies for invalidating and defending patents before the U.S. Patent and Trademark Office. For example, Lindsay has represented clients in instituting reexamination proceedings concurrent with their on-going defense in patent litigation before the Federal courts..
Mr. Adams also has experience in due diligence reviews of patent portfolios and counseling of clients on patents and patent-related FDA matters. For example, Lindsay has counseled clients on the availability of patent term extensions under the Food, Drug and Cosmetic Act, which compensates patentees for the loss of patent term while awaiting FDA approval. Lindsay has also lectured on non-first-to-file ANDA applicants possibly using post-grant proceedings against first-to-file ANDA applicants who delay marketing the generic version of a drug to thwart competition in the marketplace.
Lindsay has lectured in Japan on U.S. Patent Law and on pre-litigation strategies for Japanese companies who may face assertions of patent infringement in the US. Lindsay has also co-authored several published articles including: “Medical Diagnostic Claims Patent-Eligible After Bilski?” and “Patent Reform Efforts Not Entirely Popular."